A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Amgen

Status and phase: Completed; Phase 2

Conditions: Behcet Syndrome

Treatments: Drug: Apremilast (CC-10004); Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00866359

EudraCT#: 2008-002722-11

CC-10004-BCT-001

Details and patient eligibility

About

The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.

Enrollment: 111 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Behçet Disease. At the time of diagnosis, subjects must meet the international study group criteria for Behçet Disease
• Females of childbearing potential (FCBP) must have negative pregnancy tests and agree to use two forms of contraception throughout the study.
• Males must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP
• Laboratory criteria: Hgb ≥ 9 g/dL, WBC count ≥ 3000 /microL and ≤14,000/microL, platelet count ≥ 100,000 /microL,, serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L), total bilirubin ≤ 2.0 mg/dL, AST and ALT ≤ 1.5 X ULN
• Two or more oral ulcers over the 28 day period before screening, with or without current treatment
• Two or more oral ulcers at the time of randomization (Visit 2, Baseline)

Exclusion criteria

• Pregnant or breast feeding
• Any condition which places the subject at risk
• Systemic fungal infection
• History of TB infection within 3 years
• History of recurrent bacterial infection
• Mycobacterium TB as indicated by a positive PPD skin test
• History of incompletely treated Mycobacterium tuberculosis
• Clinically significant chest x-ray abnormality at screening.
• Clinically significant ECG abnormality at screening
• History of HIV infection
• History of congenital or acquired immunodeficiency
• Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening
• Antibodies to Hepatitis C at screening
• History of malignancy (except for treated basal-cell skin carcinomas > 3 years prior to screening)
• Any active major organ involvement of Behçet Disease
• Use of concomitant immune modulating therapy or topical corticosteroids.
• Use of ocular corticosteroids
• Use of any investigational medication within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

111 participants in 2 patient groups, including a placebo group

A. Apremilast

Active Comparator group

Treatment:

Drug: Apremilast (CC-10004)

B. Placebo Comparator

Placebo Comparator group

Treatment:

Drug: Placebo